@article {MASUISHI6501, author = {TOSHIKI MASUISHI and HIROYA TANIGUCHI and TETSUYA ETO and AZUSA KOMORI and SEIICHIRO MITANI and HIROKO HASEGAWA and YUKIYA NARITA and MAKOTO ISHIHARA and TSUTOMU TANAKA and SHIGENORI KADOWAKI and TAKASHI URA and MASASHI ANDO and MASAHIRO TAJIKA and MOTOO NOMURA and YOZO SATO and HIDEYUKI MISHIMA and KEI MURO}, title = {Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases}, volume = {38}, number = {11}, pages = {6501--6506}, year = {2018}, doi = {10.21873/anticanres.13014}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Anti-EGFR antibodies or bevacizumab comprise first-line treatment for patients with RAS wild-type colorectal liver metastases (CLM). Which marker better predicts efficacy, early tumor shrinkage or morphologic response, still remains unclear. Patients and Methods: We retrospectively evaluated 155 patients with KRAS exon 2 wild-type CLM treated with bevacizumab (BEV group) or anti-EGFR antibodies (EGFR group). Three radiologists independently assessed early tumor shrinkage (ETS) and early optimal morphologic response (EOMR) from baseline and first follow-up CT scan. Results: Patients with ETS had longer progression-free survival (PFS) than those without ETS [hazard ratio (HR)=0.69] and ETS tended to be observed in the EGFR group, while patients with EOMR had longer PFS than those without EOMR (HR=0.64) and EOMR tended to be observed in the BEV group. Conclusion: Among patients with KRAS exon 2 wild-type CLM, EOMR and ETS may predict better PFS, especially in patients treated with bevacizumab and anti-EGFR antibodies, respectively.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/11/6501}, eprint = {https://ar.iiarjournals.org/content/38/11/6501.full.pdf}, journal = {Anticancer Research} }